Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • Inhibitor of differentiation-1 (Id1) sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma

    Román M (1), López I (1), Guruceaga E (2), Baraibar I (3), Ecay M (4), Collantes M (4), Nadal E (5), Vallejo A (1), Cadenas S (6), Echávarri-de Miguel M (6), Jang JH (7), San Martín-Uriz P (8), Castro-Labrador L (9), Vilas-Zornoza A (10), Lara-Astiaso D (11), Ponz-Sarvise M (12), Rolfo C (13), Santos ES (14), Raez LE (15), Taverna S (16), Behrens C (17), Weder W (18), Wistuba II (19), Vicent S (20), Gil-Bazo I (21).

    (1) Program of Solid Tumors and Biomarkers, Center for Applied Medical Research.
    (2) Bioinformatics Platform, CIMA, University of Navarra.
    (3) Department of Oncology, Clínica Universidad de Navarra.
    (4) Nuclear Medicine, Clínica Universidad de Navarra.
    (5) Medical Oncology, Catalan Institute of Oncology.
    (6) Program of Solid Tumors, Center for Applied Medical Research.
    (7) Department of Thoracic Surgery, University Hospital of Zurich.
    (8) Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA).
    (9) Oncohematology, Center for Applied Medical Research (CIMA).
    (10) Advanced Genomics, Center for Applied Medical Research (CIMA).
    (11) Center for Applied Medical Research, Advanced Genomics Laboratory, University of Navarra.
    (12) Medical Oncology, Clinica Universidad de Navarra/Center for Applied Medical Research (CIMA), University of Navarra.
    (13) Thoracic Medical Oncology and Early Clinical Trials, Marlene and Stweart Greenebaum Comprehensive Cancer Center.
    (14) Lynn Cancer Institute.
    (15) Medical Director, Memorial Cancer Institute, Memorial Health Care System.
    (16) Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council.
    (17) Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center.
    (18) Division of Thoracic Surgery, University Hospital Zürich.
    (19) Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center.
    (20) Program of Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra.
    (21) Department of Oncology, Clínica Universidad de Navarra

    Cancer Research 18 de DICIEMBRE de 2018

  • Surface scanning for 3D dose calculation in intraoperative electron radiation therapy

    García-Vázquez V (1), Sesé-Lucio B (2), Calvo FA (2,3,4,5), Vaquero JJ (2,6), Desco M (2,6,7,8), Pascau J (2,6,7).

    (1) Hospital General Universitario Gregorio Marañón, Unidad de Medicina y Cirugía Experimental (Instituto de Investigación Sanitaria Gregorio Marañón), Madrid, Spain.
    (2) Hospital General Universitario Gregorio Marañón, Unidad de Medicina y Cirugía Experimental (Instituto de Investigación Sanitaria Gregorio Marañón), Madrid, Spain.
    (3) Departamento de Oncología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
    (4) Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
    (5) Clínica Universidad de Navarra, Madrid, Spain.
    (6) Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Madrid, Spain.
    (7) Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
    (8) Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

    Radiation Oncology 07 de DICIEMBRE de 2018

  • Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG

    Law I (1), Albert NL (2), Arbizu J (3), Boellaard R (4,5), Drzezga A (6), Galldiks N (7,8), la Fougère C (9), Langen KJ (8,10), Lopci E (11), Lowe V (12), McConathy J (13), Quick HH (14), Sattler B (15), Schuster DM (16), Tonn JC (17), Weller M (18).

    (1) Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, 9, Blegdamsvej, 2100-DK, Copenhagen Ø, Denmark.
    (2) Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany.
    (3) Department of Nuclear Medicine, Clínica Universidad de Navarra, University of Navarre, Pamplona, Spain.
    (4) Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.
    (5) Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
    (6) Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
    (7) Department of Neurology, University Hospital Cologne, Cologne, Germany.
    (8) Institute of Neuroscience and Medicine (INM-3, -4), Forschungszentrum Julich, Julich, Germany.
    (9) Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Tübingen, Tübingen, Germany.
    (10) Department of Nuclear Medicine, RWTH University Aachen, Aachen, Germany.
    (11) Department of Nuclear Medicine, Humanitas Clinical and Research Hospital, Rozzano, Italy.
    (12) Department of Radiology, Nuclear Medicine, Mayo Clinic, Rochester, MN, USA.
    (13) Division of Molecular Imaging and Therapeutics, University of Alabama at Birmingham, Birmingham, AL, USA.
    (14) High-Field and Hybrid MR Imaging, University Hospital Essen, Essen, Germany.
    (15) Department for Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
    (16) Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.
    (17) Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany.
    (18) Department of Neurology, University Hospital Zurich, Zurich, Switzerland.

    European Journal of Nuclear Medicine and Molecular Imaging 05 de DICIEMBRE de 2018

  • CT screening for lung cancer: comparison of three baseline screening protocols

    Henschke CI (1,2,3), Yip R (4), Ma T (4,5), Aguayo SM (6), Zulueta J (7), Yankelevitz DF (4); Writing Committee for the I-ELCAP Investigators.

    (1) Icahn School of Medicine at Mount Sinai, New York, NY, USA. Claudia.
    (2) Phoenix Veterans Affairs Health Care System, Phoenix, AZ, USA. Claudia.
    (3) Department of Radiology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY, 10029, USA. Claudia.
    (4) Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (5) Department of Diagnostic Ultrasound, Tong Ren Hospital, Capital Medical University, Beijing, 100730, China.
    (6) Phoenix Veterans Affairs Health Care System, Phoenix, AZ, USA.
    (7) Clinica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Navarra, Spain.

    European Radiology 03 de DICIEMBRE de 2018

  • Evaluation of RETICs Glaucoma Diagnostic Calculators in Preperimetric Glaucoma

    Moreno-Montañés J (1), García-Nieva A (1), Osio IA (2), Guarnieri A (1), Morilla-Grasa A (2), García-Granero M (3), Antón A (2).

    (1) Department of Ophthalmology, Clínica Universidad de Navarra, Medical School, University of Navarra, Pamplona, Spain.
    (2) Institut Catalá de Retina, Universitat Internacional de Catalunya, Barcelona, Spain.
    (3) Unidad de Estadística, Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain.

    Translational Vision Science & Technology 30 de NOVIEMBRE de 2018

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra